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Decades of cardiovascular research have shown that variable and flexible levels of protein
phosphorylation are necessary to maintain cardiac function. A delicate balance between
phosphorylated and dephosphorylated states of proteins is guaranteed by a complex
interplay of protein kinases (PKs) and phosphatases. Serine/threonine phosphatases, in
particular members of the protein phosphatase (PP) family govern dephosphorylation
of the majority of these cardiac proteins. Recent findings have however shown that
PPs do not only dephosphorylate previously phosphorylated proteins as a passive
control mechanism but are capable to actively control PK activity via different direct and
indirect signaling pathways. These control mechanisms can take place on (epi-)genetic,
(post-)transcriptional, and (post-)translational levels. In addition PPs themselves are
targets of a plethora of proteinaceous interaction partner regulating their endogenous
activity, thus adding another level of complexity and feedback control toward this system.
Finally, novel approaches are underway to achieve spatiotemporal pharmacologic control
of PPs which in turn can be used to fine-tunemisleaded PK activity in heart disease. Taken
together, this review comprehensively summarizes the major aspects of PP-mediated PK
regulation and discusses the subsequent consequences of deregulated PP activity for
cardiovascular diseases in depth.
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INTRODUCTION
Myriads of studies starting from the late 1930s have unequivocally shown that protein kinases (PKs)
are essential for cellular homeostasis not only in the heart but in virtually any tissue of the body
(Cori et al., 1939; Rapundalo, 1998; Cohen, 2002a; Harvey, 2004; Johnson, 2009; Sato et al., 2015).
We have now gathered a deep understand how PKs work in the context of cardiovascular diseases
(CVDs) and consequently it is anticipated that PKs may serve as the pharmacological drug target of
the twenty-first century (Cohen, 2002a,b; Force et al., 2004; Belmonte and Blaxall, 2011; Roskoski,
2015). Although discovered at an equally early time point in scientific history, protein phosphatases
(PPs) have received much less attention in terms of functional studies and for consideration as
potential drug targets. This is somewhat astonishing as (phospho-)proteomic studies suggested
that nearly one third of all protein phosphorylation events is reversible (Sefton, 2001; Olsen et al.,
2006) and it seems likely that targeting phosphatases in CVDs can be similarly promising. One
explanation for this observation can be certainly attributed to the difference in substrate selection
between PKs and PPs (Brinkworth et al., 2003; Zhu et al., 2005; Ubersax and Ferrell, 2007;
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Roy and Cyert, 2009; Slupe et al., 2011; Li et al., 2013; Peti
et al., 2013; Palmeri et al., 2014). While more than 400 available
PKs often recognize decent consensus sequences in their
target proteins, a far smaller number of phosphatases does
not rely on specific enzyme-substrate recognition but mainly
interact via so called phosphatase interacting proteins (PIPs)
with their respective substrate, thus decreasing druggability
enormously in comparison to PKs (Cohen, 2002c; Chatterjee
and Kohn, 2013; De Munter et al., 2013; Li et al., 2013).
Nevertheless recent developments have revealed exciting
opportunities for the application of phosphatase-regulating
drugs in CVDs and will therefore be discussed at the end of this
review.
Protein phosphatases can be divided into three different
subgroups, namely serine-threonine, tyrosine, and dual-specific
phosphatases depending on their endogenous phosphorylation
substrate (Maillet et al., 2008; Auger-Messier et al., 2013;
Heijman et al., 2013; Senis, 2013). Thereby more than 98% of
dephosphorylation events are carried out by serine-/threonine
phosphatases and within this group PP 1, 2A, and 2B (PP1,
PP2A and PP2B, also called calcineurin) amount to 90%
of all dephosphorylation activity in the heart (Cohen, 1989;
MacDougall et al., 1991). As a consequence this review will
focus on the latter PPs and their role as cellular opponents
of the aforementioned PKs in the healthy and diseased heart.
Nevertheless we would like to refer the reader to some
recent excellent reviews and research publication showing the
physiological and pathophysiological importance of phosphatases
which are not discussed in this review (Pulido and Hooft
van Huijsduijnen, 2008; Patterson et al., 2009; Senis, 2013;
Lauriol et al., 2015). Before we will deeply dive into the
functional role of PP1, PP2A, and PP2B and their potential
as drug target in CVDs, we will shortly recapitulate the
structure of these enzymes which are virtually all working as
holo-enzymes as this is crucial for the understanding of the
following chapters. Figure 1 shows a schematic drawing of the
mouse representative PP1, PP2A, and PP2B holoenzymes known
so far.
In mammals, the catalytic PP1 subunit is encoded by three
separate genes (PPP1CA, PPP1CB, and PPP1CC) which seem
to have distinct subcellular functions as suggested by initial
studies using isoform specific knock-down and knock-out studies
(Aoyama et al., 2011; Liu et al., 2015). Nevertheless there
is neither detailed information available about spatiotemporal
control of PP1 isoforms in the healthy or diseased heart nor
insights into the molecular mechanism at this time (Luss
et al., 2000). Further diversification of PP1 isoforms is achieved
by alternative splicing of PPP1CA (PP1a1 3) and PPP1CC
(PP1g1=2). PP1g2 seems to be the only tissue-specific expressed
PP1 (brain and testis) while all other isoforms are expressed
ubiquitously (Cohen, 2002c; Ceulemans and Bollen, 2004;
Korrodi-Gregorio et al., 2014). Multiple studies have suggested
that there is actually no freely available PP1 within the cardiac
cell but rather a competition of >150 regulatory subunits
to form a holo-complex with the PP1 catalytic subunits.
These regulatory subunits determine subcellular localization
and substrate specificity of the different PP1 isoform catalytic
subunits. A series of excellent reviews gives a comprehensive
overview about this aspect of PP1 (Ceulemans and Bollen,
2004).
The composition of the PP2A holo-enzyme is even more
complex. It can be either a heterodimer consisting of the catalytic
(PP2A-Ca or Cb) and the structural scaffold (PP2A-Aa or Ab)
or a trimer consisting of the catalytic, the structural scaffold
and another regulatory subunit (PPP2RX; Herzig and Neumann,
2000; Heijman et al., 2013). The importance of PP2a regulation
becomes obvious since altered expression and activities are closely
associated with heart diseases (Lei et al., 2015). Intriguingly PP1
and PP2A seem to share a couple of substrates together (Heijman
et al., 2013). If this is due to compensatory mechanisms after
genetic knockdown or knockout of single PP1/PP2A genes or
caused by lack of specificity of the available pharmacological
inhibitors has still to be determined. For further reading about the
molecular mechanisms underlying PP2A regulation in the heart
we would again like to recommend another set of enlightening
reviews (Janssens andGoris, 2001; DeGrande et al., 2013; Lei et al.,
2015).
Finally we would like to highlight PP2B (or calcineurin) as
an essential cardiac PP which links Ca2+ and phosphorylation-
dependent signaling pathways. Initially mainly studies identified
calcineurin as a regulator of Ca2+ mediated gene transcription
during cardiac remodeling, but recently calcineurin was also
shown to directly act as an essential enzyme for reversible cardiac
protein phosphorylation, e.g., at the cardiac L-Type Ca2+-channel
(Wang et al., 2014). Heart-restricted calcineurin overexpression
in mice lead to cardiac remodeling, arrhythmic events and
premature, sudden cardiac death (Molkentin, 2000). Again, PP2B
is mainly active as a holo-enzyme consisting of one of the three
different catalytic isoforms CNAa, b or g, the Ca2+-binding
subunit (CNBa=b) and sometimes another regulatory protein, e.g.,
AKAP or Cain (Lim andMolkentin, 1999; Wolska, 2009; Heineke
and Ritter, 2012; Wang et al., 2014).
After clarifying the functional impact and physiological
importance of PPs in the heart, we will now move on to
discuss which cardiac proteins are targets of reversible protein
phosphorylation by PKs and PPs and how this may relate to CVD
pathology.
PROTEIN PHOSPHATASES COUNTERACT
PROTEIN KINASE MEDIATED PROTEIN
PHOSPHORYLATION IN THE HEART
One of the hallmarks of CVDs is altered phosphorylation of
cardiac proteins (Rapundalo, 1998; Luo and Anderson, 2013).
Thereby most of the knowledge stems from studies of isolated
cardiac myocytes, while studies about the substrates of reversible
phosphorylation in cardiac fibroblasts, endothelial and smooth
muscle cells are rather limited. Table 1 gives a comprehensive
and compartment-sorted overview about PP1, PP2A, and
PP2B substrates in cardiac cells. In this chapter we highlight
some important examples of phosphatase-dependent substrate
regulation in cardiac cells and visualize them additionally in
Figure 2.
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FIGURE 1 | Holoenzyme composition of protein phosphatases. The schematic drawing of the holoenzyme composition of PP1, PP2A and PP2B (Calcineurin)
indicates the combinatorial complexity of the different catalytic and regulatory protein phosphatase subunits. A detailed description of the underlying nomenclature
and the nature of the regulatory subunits can be found in Heijman et al. (2013).
The L-Type Calcium Channel,
Na+/K+-ATPase and Other Ion
Channels—Reversible Protein
Phosphorylation at the Plasma Membrane
Reversible phosphorylation has been shown for a huge subset of
different ion channels and their respective subunits. While the
kinases required for phosphorylation have often been identified,
the exact nature and contribution of phosphatases remained
enigmatic due to the aforementioned reasons. The best studied
examples of reversible protein phosphorylation at the plasma
membrane are therefore the L-Type calcium channel (CaV1.2)
and the Na+/K+-ATPase dependent substrates in cardiac cells.
Phosphorylation at the a-Subunit of CaV1.2 takes place on
multiple residues including Ser1512 and Ser1570 (CaMKII) as
well as Ser1866 and Ser1928 (PKA; Chen et al., 2002; Yang et al.,
2005; Lee et al., 2006; Lemke et al., 2008; Blaich et al., 2010;
Minobe et al., 2014). There is still controversy which of these
phosphorylation sites is the most important one for regulation
of the CaV1.2 function, but most studies hint at an essential role
of Ser1928 (Yang et al., 2005; Hulme et al., 2006; Lemke et al.,
2008; Xu et al., 2010). It seems as if PP1, PP2A, and even PP2B
can bind to this region and regulate dephosphorylation levels in
concert (Davare et al., 2000; Hall et al., 2006; Tandan et al., 2009;
Shi et al., 2012). It was reported that PP1 and PP2A act directly on
the phosphorylation level of CaV1.2 and PP2B may have rather
indirect effect by blocking PP1 and PP2A binding sites on the
one hand and controlling CaV1.2 expression level via the CREB
signaling pathway on the other hand (Tandan et al., 2009; Wang
et al., 2014). Spatiotemporal control of PP2A activity at the CaV1.2
alpha-subunit is known to be mediated via the B56 (all isoforms)
or PR59 subunits, while the mechanism of regulation of PP1 is
still unknown (Hall et al., 2006; Xu et al., 2010). In general, PP2A-
mediated dephosphorylation leads to downregulated CaV1.2
activity (Heijman et al., 2013). Finally pharmacological inhibition
studies suggested that aforementioned PPs may play a role for
dephosphorylation of basal as well as adrenoceptor induced
CaV1.2 phosphorylation, which renders them different from PKA
and CaMKII, that were shown to be either more important
for basal (CaMKII) or adrenoceptor induced (PKA) CaV1.2
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TABLE 1 | Targets for reversible cardiac protein phosphorylation.
Protein Reported kinase activity Phosphorylation site Reported phosphatase
activity
Reference
Aurora B n.d. n.d. PP1 Murnion et al. (2001)
CaV1.2 a CaMKII Ser1512, Ser1570 PP1
PP2A
PP2B
Davare et al. (2000), Kamp and Hell (2000), Chen
et al. (2002), Yang et al. (2005, 2007), Hall et al.
(2006), Hulme et al. (2006), Lee et al. (2006), Sun
et al. (2006), Lemke et al. (2008), Tandan et al.
(2009), Blaich et al. (2010), Xu et al. (2010),
Brandmayr et al. (2012), Shi et al. (2012), Minobe
et al. (2014)
PKA Ser1574, Ser1866,
Ser1928
PP1
PP2A
PKC Ser1928 PP1 (major)
PP2A (minor)
PKG Ser1928
Akt/PKB n.d. n.d.
CaV1.2 b PKC Ser496 PP1
PP2A
Gerhardstein et al. (1999), Grueter et al. (2006),
Yang et al. (2007), Abiria and Colbran (2010)
CaMKII Thr498
PKA Ser458, Ser478, Ser479
PKG Ser496
cMyBP-C PKA
PKC
Ser282
Ser273 (HF)
Ser302 (HF)
PP1
PP2A
Mohamed et al. (1998), Florea et al. (2012),
Heijman et al. (2013)
Cold shock domain
protein A
CSDA
Bcr-Abl kinase
PI3K/Akt
Ribosomal S6 kinase (RSK)
Ser134 PP1 Sears et al. (2010), Chiang et al. (2015)
Connexin 43 PKC Ser368 PP1
PP2A
Ai and Pogwizd (2005), Ai et al. (2011)
PKA Ser262
CREB PKA
PKC
Casein kinase II
CaMKII
P90 (RSK)
Ser133 PP1
PP2A
Montminy et al. (1990), Miller et al. (1998), Li et al.
(2006)
eIF2a n.d. n.d. PP1 Ceulemans and Bollen (2004)
FAK n.d. n.d. PP1a in vitro Yamakita et al. (1999)
Glycogen synthase
kinase
PKA Ser67
Ser48
PP1
PP2A
Woodgett and Cohen (1984), Walker et al. (2000)
HDAC4 CKIP
PKA
CaMKII
Ser246
Ser467
Ser632
PP2A Zhang et al. (2002), Backs et al. (2006)
Histone3 CaMKII Thr3
Ser28
Ser10
PP1 Ceulemans and Bollen (2004), Awad et al. (2013)
I-1 PKA Thr35 PP2A
PP2B
El-Armouche et al. (2006a), Wittkopper et al.
(2010a)
PKCa Ser67
Na+/K+ ATPase PKC Ser18 PP2A Palmer et al. (1991), Feschenko and Sweadner
(1997)
NaV1.5 CaMKII Ser571
Thr594
Ser516
n.d. Murray et al. (1997), Zhou et al. (2000), Baba
et al. (2004), Wagner et al. (2006), Hund et al.
(2010), Ashpole et al. (2012), Toischer et al. (2013)
PKA Ser525
Ser528
PKC n.d.
NCX1 PKA (in vitro), PKC Thr731 (in vitro) PP1
PP2A
PP2B
Palmer et al. (1991), Schulze et al. (2003), Wei
et al. (2003, 2007), Shigekawa et al. (2007),
Zhang and Hancox (2009), Wanichawan et al.
(2011)
Neurabin P70S6 kinase n.d. PP1 McAvoy et al. (1999), Sakisaka et al. (1999), Oliver
et al. (2002)
PKA Ser461
(Continued)
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TABLE 1 | Continued
Protein Reported kinase activity Phosphorylation site Reported phosphatase
activity
Reference
NFATs PKA
GSK3b
DYRK1/2
CK1
MEKK1
JNK
P38MAPK
multiple PP2B Beals et al. (1997), Chow et al. (1997, 2000), Zhu
et al. (1998), Chow and Davis (2000), Gomez del
Arco et al. (2000), Sheridan et al. (2002), Yang
et al. (2002), Okamura et al. (2004), Gwack et al.
(2006)
PDE4D3 PKA Ser13
Ser54
PP1
PP2A
Egloff et al. (1997), Carlisle Michel et al. (2004),
Dodge-Kafka et al. (2006), De Arcangelis et al.
(2008)
ERK5 Ser579
PDE5A n.d. n.d. PP1 Chiang et al. (2015)
Phospholemman PKA Ser68 PP1 Palmer et al. (1991), El-Armouche et al. (2011)
PKC Ser63
Ser68
PLB PKA Ser16 PP1
PP2A
MacDougall et al. (1991), Luo et al. (1994),
Jackson and Colyer (1996), Chu and Kranias
(2002)
CaMKII Ser17
PMCA PKA
PKC
n.d. PP1
PP2A
Zylinska et al. (1998), Zylinska and Soszynski
(2000)
P70S6 Kinase n.d. n.d. PP1
PP2A
Bettoun et al. (2002)
Retinoblastoma
protein (Rb)
CDK Thr320 PP1 Liu et al. (1999), Ceulemans and Bollen (2004)
RyR2 PKA Ser2808
Ser2030
PP1
PP2A
PP2B
Marx et al. (2000), Pare et al. (2005),Xiao et al.
(2005, 2006), Meng et al. (2007), Liu et al. (2011,
2014), Zhang et al. (2012)
CaMKII Ser2814
SERCA2a CaMKII Ser38
(Ser167, Ser531! in
vitro)
n.d. Brandl et al. (1986), Narayanan and Xu (1997)
SF2/ASF PKA n.d. PP1 Gu et al. (2011), Huang et al. (2014)
Tn-inhibitor (TnI) PKA Ser23
Ser24
PP1
PP2A
Cole and Perry (1975)
T-type calcium
channel (Cav3.2)
PKA Ser1107
Thr2214
Ser1144
n.d. Chemin et al. (2007), Hu et al. (2009)
Vitamin D receptor P70S6
PI-3 kinase
B/Akt
n.d. PP1
PP2A
Bettoun et al. (2002)
Yotiao/KCNQ1 PKA Ser27 PP1 Westphal et al. (1999), Marx et al. (2002),
Terrenoire et al. (2009)
This table lists currently known substrates, which PK-mediated phosphorylation is counteracted by PP1, PP2A, or/and PP2B.
phosphorylation (Brandmayr et al., 2012). As tight control of
CaV1.2 activity during EC-coupling is essential and deregulated
CaV1.2 function has been shown in a multitude of different
CVDs, e.g., hypertension, cardiac arrhythmia and heart failure,
specific targeting of PP-CaV1.2 interactions might be a versatile
drug targeting in the future (Splawski et al., 2004; Tang et al.,
2008; Domes et al., 2011; Hong et al., 2012; Tajada et al.,
2013).
Another important target for reversible dephosphorylation at
the plasma membrane is the Na+/K+-ATPase, which can be
either indirectly regulated via PP1-mediated dephosphorylation
of the Na+K+-ATPase subunit phospholemman at position Ser68
or by direct recruitment of PP2A via its subunit PP2A-B56
and subsequent dephosphorylation at position Ser18 (Neumann
et al., 1999; El-Armouche et al., 2006a; Bhasin et al., 2007).
Interestingly binding of PP2A to Na+K+-ATPase diminishes
binding of arrestin, thus increasing membrane localization of the
pump and thereby actively modulating function of the Na+K+-
ATPase (Kimura et al., 2011). The above mentioned studies also
provided an important breakthrough in better understanding
the role of reversible Na+K+-ATPase phosphorylation for CVD
development. The described mechanism is markedly perturbed
in failing hearts favoring phospholemman dephosphorylation
and Na+K+-ATPase deactivation and thus may contribute to
maladaptive hypertrophy and arrhythmogenesis via chronically
increased intracellular Na+ and Ca2+ concentrations (Neumann
et al., 1999; Schwinger et al., 2003; Cheung et al., 2010; El-
Armouche et al., 2011).
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FIGURE 2 | Protein phosphatase inhibitor-1 (I-1) fulfills a nodal role during reversible protein phosphorylation in cardiomyocytes. On the primary level
I-1 is mainly regulated by the complex interplay of protein kinases: PKA (red color), PKC (green color) and indirectly also CaMKII (blue color) vs. protein phosphatases
2A and 2B. While PKA (and CaMKII) have activating function, PKC, PP2A, and PP2B are limiting I-1 activity. On the secondary level, CaMKII and PP2B and thus
subsequently also I-1, are regulated by intracellular calcium levels, which are mediated by a complex flux balance from internal Ca2+ stores of the sarcoplasmic
reticulum, the mitochondria and the nucleus as well as Ca2+ influx from extracellular space. In turn I-1 is mainly acting on protein phosphatase 1 which
dephosphorylates a multitude of functional proteins of the cardiomyocyte (see Table 1) and can act on different cellular functions including contraction, ion
flux/currents, transcription and/or splicing, accordingly.
Finally there are some reports indicating reversible
phosphorylation of Sodium and Potassium Channels, e.g.,
NaV1.5 and KCNQ1, that are essential for membrane excitation
(Murray et al., 1997; Terrenoire et al., 2009; Marionneau et al.,
2012; Toischer et al., 2013). In case of NaV1.5 many different
phosphorylation sites have been described, with a priority
of PKA-mediated phosphorylation in peak INa and CamKII-
mediated phosphorylation during late INa (Baba et al., 2004; Bers
and Herren, 2012; Marionneau et al., 2012). To our knowledge
there is just one report about a protein tyrosine phosphatase
(PTP1) working as a counteracting phosphatase after PKA or
CamKII-mediated NaV1.5 phosphorylation, so additional studies
to identify putative PP-mediated NaV1.5 dephosphorylation
might be helpful (Jespersen et al., 2006). Even less is known with
respect to reversible KCNQ1 phosphorylation. Initial studies
show that PKA can mediated phosphorylation of KCNQ1 at
position Ser27 at its C-terminal tail, which may by counteracted
by PP1 and regulated by the accessory protein Yotiao (Marx
et al., 2002; Nicolas et al., 2008). However, more studies are
needed to understand the functional implication of reversible
phosphorylation in this macromolecular protein complex at the
plasma membrane are needed.
Phospholamban and the Ryanodine
Receptor—Reversible Protein
Phosphorylation at the Sarcoplasmic
Reticulum
Disturbed Ca2+-handling is coming along with most
CVDs and numerous studies using genetically modified or
pharmacologically treated animals have revealed the importance
of tight spatiotemporal control of the two sarcoplasmic reticulum
(SR) residing proteins ryanodine receptor type-2 (RyR2) and
phospholamban (PLB) in this context. Consequently, tremendous
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efforts have been undertaken to identify the exact contribution
of kinases and phosphatases toward deregulated phosphorylation
of the latter proteins. While the large intracellular C-terminus
of RyR2 contains multiple putative phosphorylation sites, only
three of them have been extensively studied until today. Although
still under debate, it seems as if Ser2808 and Ser2030 are the
major PKA and Ser2814 is the major CaMKII phosphorylated
site (Marx et al., 2000; Marks et al., 2002; El-Armouche and
Eschenhagen, 2009). Dephosphorylation can be carried out
by either PP1, which is targeted by spinophilin and/or PP2A
which is targeted by its subunit PR130 to the multiprotein RyR2
holo-complex (Marx et al., 2001; Reiken et al., 2003; Chiang et al.,
2014). There are no reports about calcineurin mediated RyR2
dephosphorylation but it has been suggested that deregulated
RyR2 activity can modulate calcineurin expression in turn, thus
serving as a potential hub for feedback inhibition of reversible
cardiac protein phosphorylation (Zou et al., 2011).
In contrast PP1 is the major dephosphorylating enzyme of
PLB, which critically modulates the activity of the SR Ca2+-
ATPase (SERCA2a). A small contribution has been also shown for
PP2A, but this relates to less than 30% of the dephosphorylation
events at positions Ser16 (PKA-controlled) and Thr17 (CaMKII-
controlled; MacDougall et al., 1991; Jackson and Colyer, 1996;
Chu and Kranias, 2002; Aye et al., 2012). Increased targeting of
PP1 to PLB is achieved by RGL or HSP20, which leads to reduced
SERCA2a Ca2+ uptake and thus attenuated b-AR stimulation-
induced lusitropy (Berrebi-Bertrand et al., 1998).
Troponin-I and cMyBP-C—Reversible
Protein Phosphorylation at the
Myofilaments
The most important consequences of the elevated systolic Ca2+-
level is the activation of the contractile apparatus, which is again
dependent on the amount of phosphorylation of the associated
contractile proteins, e.g., the cardiac myosin-binding protein-C
(cMyBP-C) or the Inhibitor of the Troponin complex, Troponin-
I (Barefield and Sadayappan, 2010). For the latter, PP1 seems to
preferentially dephosphorylate Ser23 and Ser24 on TnI, while the
exact substrate of PP2A is yet undetermined (Jideama et al., 2006).
Nevertheless it could be detected that targeting of PP2A is B56a-
dependent and b-AR stimulation seems to be able to dissociate
this localized interaction (Yin et al., 2010).
Phosphoproteomic studies revealed a number of putative
phosphorylation sites also for cMyBP-C (Solaro and Kobayashi,
2011). Interestingly reduced phosphorylation at position Ser282
coincides with increased PP1 and PP2A activity in patients
with atrial fibrillation (El-Armouche et al., 2006b). Similar
results were received in end-stage heart failure, however here
phosphorylation was also diminished at positions Ser273 and
Ser302 (El-Armouche et al., 2007b; Sumandea and Steinberg,
2011).
I-1 and PDE4D3—Reversible Protein
Phosphorylation in the Cytoplasm
An excellent showcase for the description of a typical substrate
for reversible phosphorylation of a cardiac protein represents the
PP1-specific inhibitor of protein phosphatase-I (I-1). I-1 fulfills
the function as a central signaling hub in feedback control of
phosphatase activity and is thus topic of a number of reviews
itself (Nicolaou et al., 2009; Wittkopper et al., 2010a, 2011).
I-1 activity depends on PKA-dependent Thr35 phosphorylation,
which seems to be mediated via AKAP18 (Endo et al., 1996;
Singh et al., 2011). During b-AR stimulation, PKA-controlled
I-1 activation and subsequent PP1 inhibition form a positive
feed-back loop amplifying the phosphorylation of substrates
like PLB, RyR2, and phospholemman (Carr et al., 2002; El-
Armouche et al., 2003). Dephosphorylation of I-1 at position
Thr35 is carried out by PP2A and PP2B, thus creating a crosstalk
between the different phosphatases as well as between PKA
and Ca2+-related second-messenger systems (via PP2B mediated
dephosphorylation of I-1; El-Armouche et al., 2006a). Moreover,
I-1 is also phosphorylated by PKCa on Ser67, this time resulting
in reduced I-1 activity and decreased PLB phosphorylation.
Conversely, the Ser67Ala substitution, preventing inactivation,
increases PLB phosphorylation (Huang and Paudel, 2000; Braz
et al., 2004). Figure 1 gives a schematic overview about the nodal
role of I-1 during reversible cardiac protein phosphorylation.
Much less is known about reversible phosphorylation of
phosphodiesterases, another important players of the adrenergic
response. PP2A could be shown as a negative regulator of PDE4D3
activity in a complex with mAKAP, RyR2 and PKA (Carlisle
Michel et al., 2004; Dodge-Kafka et al., 2006; De Arcangelis et al.,
2008). In this case PP2A activity is itself controlled by PP2B
(Dodge-Kafka et al., 2010). Further studies will be needed to
elucidate the contribution of reversible phosphorylation toward
function of cardiac PDEs, as malfunction of this enzymes can be
beneficial or detrimental in multiple CVDs.
Histone 3 and HDAC4—Reversible Protein
Phosphorylation in the Nucleus
Several studies have implicated localization and activity of
phosphatases in different compartment of the nucleus including
chromatin bound fractions (Bollen and Beullens, 2002;Moorhead
et al., 2007). There is extensive knowledge about the counteracting
role of PPs against PKs during different phases of the cell cycle
in non-cardiac cells (Ceulemans and Bollen, 2004; Novak et al.,
2010; Jeong and Yang, 2013). As adult cardiac myocytes are
mainly non-dividing cells, phosphatase targets may be different
and up to this point there are only sparse reports about nuclear
phosphatase targets in this regard (von Holtey et al., 1996;
Heineke and Ritter, 2012). An exception hereof is histone
deacetylase 4 (HDAC4), which phosphorylation status was well
studied. While CKIP and CaMKII seem to be the main kinases
phosphorylating Ser246, and Ser632, PP2A was identified as a
major phosphatase to control HDAC4 phosphorylation status
and subsequent subcellular localization, thus modulating HDAC4
activity (Paroni et al., 2008; Ling et al., 2012; Liu and Schneider,
2013; Kreusser and Backs, 2014). Knockdown experiments of
PP1 did not reveal a significant contribution toward HDAC4
dephosphorylation. This might however be different for another
important phosphatase substrate of the nucleus, which is histone
3 (H3). Phosphorylation of H3 occurs at multiple positions,
including Ser10 and Ser28 (Awad et al., 2013; Korrodi-Gregorio
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et al., 2014). PP1 was reported to significantly contribute toward
dephosphorylation of at least Ser10 in non-cardiac cells rendering
it a potential target also in cardiac myocytes (Awad et al., 2013).
In summary PPs may act as important and rapid modifiers of
the epigenetic code and predispose DNA and protein sequences
for subsequent methylation—a concept that is also known as the
methyl-phospho-switch hypothesis (Chen et al., 2008; Sawicka
and Seiser, 2014).
Nuclear Factors of Activated T-Cells
(NFATs)—Regulation of Transcription by
Ca2+-dependent Dephosphorylation
Nuclear factors of activated T-cells (NFATs) are a family of
transcription factors in which the nuclear localization signals
(NLS) are masked by multiple phosphorylations in their serine-
rich domains. Upon activation of PP2B by Ca2+/calmodulin,
they are dephosphorylated, leading to their nuclear translocation,
initiation of transcription and induction of cardiac hypertrophy
as well as electrical remodeling (Heineke and Molkentin, 2006;
Heineke and Ritter, 2012). A potential role in cardiac hypertrophy
has been shown for NFATc2, NFATc3, and NFATc4. A number
of PKs have been inflicted in cardiac NFAT phosphorylation,
among them PKA, GSK3b, DYRK1/2, CK1, MEKK1, JNK and
P38MAPK, and some isoform specificity is present. Importantly,
PKA and DYRK1/2 can act as priming kinases, enabling other
kinases to access the NFAT phosphorylation sites (Pan et al.,
2013). The importance of PP2B/NFAT signaling in cardiac
hypertrophy was first recognized in 1998, when Molkentin et al.
(1998) demonstrated that overexpression of activated PP2B of
NFATc4 lead to cardiac hypertrophy. Later it became clear that
NFATc3 as well as c4, but not c2 are necessary for cardiac
hypertrophy in multiple models (Wilkins et al., 2004; Bourajjaj
et al., 2008). Moreover, PP2B/NFAT signaling plays an important
role in shaping physiological cardiac repolarization (Rossow et al.,
2006) as well as in the generation of an arrhythmogenic substrate
in heart failure (Rossow et al., 2004). Since cardiomyocytes
dramatically increase their intracellular Ca2+ concentration
during each heartbeat, an important problem to be solved is
the question whether the “contractile Ca2+” released by LTCC
and RyR2 or a different pool of Ca2 regulated by LTCC and/or
canonical transient receptor potential channels (TRPC1, 3 or 6)
activate PP2B in CVD (Rossow et al., 2004).
Connexin 43 and SAP97—Reversible
Protein Phosphorylation at Cell–Cell
Contacts
Cardiac electrical excitation is mainly conducted from cell to cell
by connexins. In heart especially connexins 43 and 45 fulfill an
important function for conduction and increased phosphatase
activity of either PP1 or PP2A was shown to induce conduction
slowing possibly due to influence on protein stability and nearby
channel activation (Jeyaraman et al., 2003; Ai and Pogwizd,
2005; Ai et al., 2011). Decreased connexin expression and
phosphorylation was recently identified as a novel inducer of
arrhythmic events (Delmar and Makita, 2012; Remo et al., 2012).
Another important protein involved in such cell-cell contacts
is synapse-associated protein 97 (SAP97). Numerous studies in
brain have suggested CaMKII dependent phosphorylation and
PP2B-mediated dephosphorylation of this scaffolding protein
(Nikandrova et al., 2010). While SAP97 is also expressed in
heart and initial studies in mice have revealed potential impact
on potassium channel function and thereby action potential
duration, there is a lack of knowledge regarding reversible SAP97
phosphorylation in the heart.
Glycogen Synthase and
Phosphorylase—Reversible Protein
Phosphorylation During Cardiac
Metabolism
Although being the first PP substrates studied in terms of
regulation and mechanism, the knowledge about functional
impact of phosphatases on proteins of the glycogen metabolism
has been underestimated for cardiac function a long time.
However, recent milestone publications have led to a revival
of the study of metabolic pathways and their contribution
toward CVDs (Kolwicz et al., 2013; Chouchani et al., 2014;
Mirtschink et al., 2015). The most important substrates of
PP1 and PP2A are glycogen synthase, glycogen phosphorylase
and to a lesser extent, phosphorylase kinase (Ceulemans and
Bollen, 2004). PP1 and PP2A-mediated dephosphorylation of
the rate-limiting enzymes of glycogen metabolism results in the
storage of glycogen, in accordance with the proposed function
of PP1 as an energy conserving enzyme (Ceulemans and Bollen,
2004). Future studies will be necessary to understand the exact
contribution of the different phosphatases in cardiac cells in this
process and to translate these findings for the understanding of
pathophysiological processes. In this regard it will also be essential
to check reversible phosphorylation in other metabolic pathways,
e.g., lipid, amino acid, and nucleotide metabolism.
While this chapter indicated the widespread target portfolio of
PPs in the heart, the molecular regulation of PPs themselves is at
least equally important for cardiac physiology and manifestation
of CVDs. Therefore we are going to review the multiple
checkpoints of PP regulation in the heart in the light of PP-
dependent PK activity regulation.
REGULATING THE REGULATORS:
MOLECULAR CONTROL OF PROTEIN
PHOSPHATASE ACTIVITY IN THE
HEALTHY AND DISEASED HEART
PPs themselves can be regulated at multiple checkpoints. We will
first discuss and highlight some of this regulative mechanisms
and subsequently summarize the consequences of deregulated
phosphatase activity in CVDs.
The perhaps most obvious but still not really well studied
mechanism of transcriptional control is the expression of different
isoforms of the catalytic subunits of PP1, PP2A, and PP2B
(Cohen, 2002c; Korrodi-Gregorio et al., 2014). Especially for
PP1, isoform analysis in non-cardiac cells has shown difference
in subcellular distribution of catalytic isoforms and response
toward cellular stressors like hypoxia and/or apoptosis (Wang
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et al., 2001; Comerford et al., 2006; Iacobazzi et al., 2015). The
most obvious but however not really well studied mechanism
of transcriptional control is the expression of different isoforms
of the catalytic subunits of PP1, PP2A, and PP2B (Herzig and
Neumann, 2000; Felkin et al., 2011; DeGrande et al., 2013;
Korrodi-Gregorio et al., 2014). Especially for PP1, isoform
analysis in non-cardiac cells has shown difference in subcellular
distribution of catalytic isoforms and response toward cellular
stressors like hypoxia and/or apoptosis (Ceulemans and Bollen,
2004; Trinkle-Mulcahy et al., 2006; Djouder et al., 2007; Iacobazzi
et al., 2015). Mutants of different PP1 isoforms in Drosophila
or mice give rise to apparently different phenotypes (Raghavan
et al., 2000; Kirchner et al., 2007). For cardiac myocytes there
is yet very limited evidence that isoform-specific distribution
of PP catalytic subunits underlies functional implication during
CVDs, thus awaiting further examination in suitable cellular or
animal models. So far preliminary reports suggest predominant
expression of PP1a in myofibrillar, PP1b in longitudinal SR
and PP1g in the junctional SR fraction under basal conditions
(Aoyama et al., 2011). However, the small number of PP1c
isoforms, their near 90% amino-acid sequence identity and
their broad and similar substrate specificities in vitro support
the current hypothesis that it is predominantly the regulatory
subunits with which PP1c interacts that controls the specificity
and enormous diversity of PP1 function. To our knowledge
there is only one report about isoform specific distribution of
PP2A or PP2B catalytic subunits in cardiac cells until today
enforcing the importance of regulatory subunits for substrate
specificity and subcellular distribution also for the two latter
phosphatases (DeGrande et al., 2013). In addition there is some
limited knowledge about the characteristic of the calcineurin
promoter, while we are not aware of any reports about PP1
or PP2A promoter analysis in cardiac cells leaving a huge
unexplored research field of PP activity regulation (Oka et al.,
2005). Finally some sparse studies hint at epigenetic regulation
mechanisms of, e.g., PP2A expression control but again specific
and detailed mechanistic studies in cardiac cells are missing
(Keen et al., 2004). Thus although deregulated expression of
PPs have been reported during a variety of different CVDs,
and the underlying mechanistic nature has not been studied in
detail yet.
An interesting opportunity of post-transcriptional PP activity
control is conducted via regulated expression of microRNAs
(miRs). However, most of the known examples in the heart have
revealed control of PP1, PP2A, and PP2B regulatory subunit
rather than catalytic subunit expression bymiRs so far. Prominent
examples are, e.g., miR-1 and miR-133 control of RyR2/PP2A
mediated arrhythmogenesis,miR-34-a control of PPP1R10 during
cardiac aging and contraction, as well as miR-212/132 control of
calcineurin activity during cardiac hypertrophy (Belevych et al.,
2011; Ucar et al., 2012; Boon et al., 2013). It is anticipated that
miR-mediated control of PP catalytic and regulatory subunitsmay
serve as a novel attractive and highly specific pharmacological
target among CVDs.
The most intensive studied way of PP activity control is,
however, post-translational PP activity control, mediated either
by a regulatory or an inhibitory subunit. Recent studies have
suggested that the number of PIPs is bigger than the number of
PP, leading to a situation of competition between the different
regulatory and inhibitory subunits for the catalytic subunits of
PPs (Ceulemans and Bollen, 2004). Genetic studies in transgenic
mice with knock-out or overexpression of PP regulatory subunits
have enforced our understanding about this process (Heijman
et al., 2013). While there are, e.g., already more than 150 known
regulatory subunits for PP1, we have decided to focus on two
complex examples of PP activity regulation that may serve a
prototype for PP regulation and inhibition, namely I-1 and
spinophilin. For a comprehensive overview we would like to
recommend some excellent reviews dedicated to posttranslational
PP activity control (Cohen, 2002c; Redden and Dodge-Kafka,
2011).
Protein Phosphatase Inhibitor-1 (I-1)
One of the best studied examples of PP-inhibitory subunits in the
heart is the I-1. Originally identified in rabbit skeletal muscle,
it’s expression has now been verified in nearly every tissue with
highest expression in skeletal muscle, adipocytes, kidney and
liver and brain (Huang and Glinsmann, 1976; Hemmings et al.,
1992; Aleem et al., 2001). Interestingly I-1 can only be found in
vertebrates and may therefore represent rather recent addition
of the fine-tuning interplay between PKA and PP1 from an
evolutionary view (Ceulemans and Bollen, 2004). I-1 is one of
the few thermostable proteins and cannot be precipitated by 1%
trichloroacetic acid (Aitken and Cohen, 1982; El-Armouche et al.,
2004;Wittkopper et al., 2011). Although being relatively small and
without any transmembrane domains, the crystal structure of I-1
could not be elucidated until recently (Huang et al., 2010). As the
exact activation and inhibitionmechanism of I-1 has been already
been described before in this review we will know focus on the
consequence of deregulated I-1 expression on PP activity and vice
versa for different CVDs.
The first example comes from failing human myocardium,
which showed hyperactive PP1 (Neumann et al., 1997; Huang
et al., 1999; Schwoerer et al., 2008). It was tempting to speculate
that I-1 might be dysregulated in heart failure and in fact I-1
mRNA and total I-1 protein amount were reduced by 60%,
and its PKA-dependent phosphorylation level even by 80%
(El-Armouche et al., 2003, 2004). The reason of decreased
I-1 phosphorylation possibly reflects desensitization of b-AR
signaling with decreased cAMP levels and PKA activation in
the failing myocardium. Additionally an increase in calcineurin
activity, especially in settings of elevated diastolic Ca2+ levels, may
contribute to the decrease in I-1 phosphorylation described above
(Lim and Molkentin, 1999). Finally I-1 protein expression was
also markedly downregulated in an experimental dog model of
heart failure arguing for a central role of I-1 mediated PP1 activity
control during heart failure (Gupta et al., 2003; El-Armouche
et al., 2007a). All these data suggest that I-1 downregulation
may be part of the desensitization process taking place among
the irregular b-adrenergic signal transduction pathway in failing
hearts. A hypothesis that could in part be validated by studies
using rats with chronic isoprenaline treatment showing decreased
I-1 expression and activation levels as well (El-Armouche
et al., 2007a). Knock-out of I-1 in mice in two different studies
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led to either none or a subtle decrease in basal contractile
parameters and a significantly blunted b-adrenergic response
(Carr et al., 2002; El-Armouche et al., 2008). Isolated atria from
I-1 deleted mice showed normal isometric force under basal and
maximally stimulated conditions but a rightward shift of the
concentration-response curve of isoprenaline (Carr et al., 2002).
Importantly, neither the b-AR density nor the PP1 protein levels
differed from wild type littermates, indicating no obvious major
compensatory changes in the I-1 KO hearts. Finally, germline
deletion of I-1 did not result in apparent heart disease and
did not negatively affect life expectancy and/or heart structure
in aged mice arguing against a causative role of diminished
I-1 expression for heart failure progression (Carr et al., 2002;
El-Armouche et al., 2008; Heijman et al., 2013). Further studies
are needed to better understand the functional implication of
I-1 deletion during experimental models of heart failure and to
elucidate if pharmacological inhibition of I-1 might be beneficial
or detrimental during initiation and progression of heart failure.
In contrast extreme overexpression of full-length I-1 (200-fold)
led to spontaneous cardiac hypertrophy and cardiac dysfunction
accompanied by compensatory PP1 expression already at young
age of 3 months (El-Armouche et al., 2008). Instead conditional
cardiomyocyte-specific and moderate overexpression of a
constitutively active I-1 (I-1c) show a hypercontractile response
comparable to PLB knock out mice but exaggerated contractile
dysfunction upon catecholamine application in young mice
and spontaneous development of dilated cardiomyopathy in
adult mice (Wittkopper et al., 2010b, 2011). A comparative PP1
upregulation could however not be detected in this mouse model.
Another study did not show any overt cardiac phenotypes in
young mice after moderate I-1 overexpression and therefore
postulated moderate I-1 overactivation/overexpression as a
potential pharmacological approach (Pathak et al., 2005). Indeed
subsequent studies usingmodels of pressure overload and chronic
isoprenaline infusion-induced heart failure, suggested that I-1
overexpression is associated with a preserved cardiac function,
an attenuated development of cardiac hypertrophy and a lower
degree of fibrosis and apoptosis (Pathak et al., 2005; Chen et al.,
2010; Ishikawa et al., 2014).
A second example of I-1 controlled PP1 activity in a
pathological condition has been described for the occurrence
and persistence of atrial fibrillation (El-Armouche et al., 2006b;
Chiang et al., 2015). Similar to the situation in failingmyocardium
some proteins which are important for Ca2+ handling, such
as the L-type Ca2+ channel or cMyBP showed increased
dephosphorylation hinting at hyperactive PPs (El-Armouche
et al., 2006b; Dobrev and Nattel, 2008; Nattel et al., 2008).
Nevertheless some other Ca2+-handling proteins like the RyR2 (at
Ser2814) or PLB (at Thr17) were in turn hyper-phosphorylated
arguing for rather subcellular than general upregulation of PP
activity (Neef et al., 2010). The exact mechanism for this
observation is however still unknown and deserves further
investigation. Another contrast to the situation in failing
myocardium were the level of I-1 as well as S67-phospho I-
1, which were unchanged between AF and non-AF patients
(Bhasin et al., 2007). Even more surprisingly, PKA-dependent
phosphorylation of I-1 at Thr35was roughly 10-fold higher in cAF
patients, which is thought to be completely suppressive for SR-
bound PP1 activity, thus leading to increased phosphorylation of
PLB (Ser16) andRyR2 (Ser2814; El-Armouche et al., 2006b; Chelu
et al., 2009; Greiser et al., 2009). Another contributor toward
RyR2 phosphorylation in cAF patients may be overactivated
CaMKII which overcomes the globally enhanced PP1 activity
causing greater steady-state RyR2 phosphorylation (Chelu et al.,
2009).
As a final example for I-1 controlled PP activity during CVDs
we have picked ventricular arrhythmias, whichmay be responsible
for almost half of death cases in patients with heart failure (Packer,
1985; Roberts-Thomson et al., 2011). In general ventricular
arrhythmias are initiated and maintained by either focal (ectopic)
or re-entry mechanisms, which have been linked to increased
diastolic SR Ca2+ leak from RyR2 and subsequent activation of
the Na+/Ca2+-exchanger (NCX) at the cellular level (Weiss et al.,
2000; Jalife et al., 2003; Prystowsky et al., 2012; Qu and Weiss,
2015). Increased and/or prolonged NCX activity may in turn lead
to delayed after-depolarizations underlying arrhythmogenesis
(Vermeulen et al., 1994; Schillinger et al., 2003; Sipido et al., 2007).
Although still under debate if hyperactivated PKAorCaMKII play
the major role for increased RyR2 activation and subsequent SR
Ca2+ leak, it is common sense that b-adrenoceptor stimulation
is the general trigger for SR Ca2+ leak in both atrial and
ventricular arrhythmias (Eisner et al., 2009; Eschenhagen, 2010;
Dobrev et al., 2011). In contrast much less is known about the
physiological and pathological role of RyR2 dephosphorylation by
phosphatases. Different studies have shown that both, PP1 and
PP2A are coupled to the RyR2 macromolecular complex (Marx
et al., 2000). Consequently, the dual PP1/PP2A inhibitor okadaic
acid increases the RyR2 open probability and phosphorylated
RyR2 subunits have been shown to be dephosphorylated using
recombinant PP1 (Sonnleitner et al., 1997).
Interestingly, I-1 deleted mice were partly protected from
structural (hypertrophy, fibrosis, and dilatation) and functional
effects (loss of inotropic response to dobutamine) of chronic
b-adrenoceptor stimulation via isoprenaline infusions with
minipumps (Wittkopper et al., 2011). In addition, injections of
increasing doses of isoprenaline with continued ECG monitoring
showed marked protection from fatal catecholamine induced
arrhythmias in I-1 knock-out mice (El-Armouche et al.,
2008). Notably, the protection from b-adrenergic-mediated
cardiotoxicity in I-1 knock-out mice was not associated with
changes in heart rate regulation. Further studies using, e.g.,
isoform-specific PP1 and/or PP2A overexpressing mice or
cardiac myocytes may help to strengthen these preliminary
results.
Spinophilin
Another fascinating example of phosphatase activity regulation
with potential implication in CVD can be found within
the interaction of spinophilin and PP1. First evidence that
spinophilin can act as a regulatory PP1 subunits stems from in
vitro co-immunoprecipitation studies using overexpressed GST-
RyR2 fusion proteins (Marx et al., 2001). While in vitro co-
incubation of spinophilin and PP1 with the model substrate
phosphorylase A led to decreased dephosphorylation activity, in
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vivo experiments showed that spinophilin acts as a scaffolding
protein to target PP1 toward its endogenous substrates, thus
rather facilitating dephosphorylation activity than decreasing it
(Feng et al., 2000; Oliver et al., 2002). Elegant studies using
different PP1/spinophilin or other PP1/PIP crystal complexes
helped to understand the underlying mechanistic principles of
these interactions (Ragusa et al., 2010, 2011).
It was shown that the C-terminal domain (aa 417–494) of
spinophilin is necessary and sufficient for complete interaction
with PP1 (Hsieh-Wilson et al., 1999). However, crystallization
studies revealed that the PP1-binding domain of spinophilin
is highly unstructured and has contact with multiple residues
on PP1. In fact, the spinophilin binding domain entirely folds
only upon binding to PP1 (Ragusa et al., 2010). Interestingly,
spinophilin does not only bind via the well-recognized RVXF
binding motif, but also by multiple interaction with the C-
terminal groove of PP1. Most importantly, despite all the above
described PP1/spinophilin interaction sites, spinophilin does not
affect the PP1 active site, nor two further putative substrate
binding sites, enabling full PP1 activitywhen bound to spinophilin
and leaving the chance for further PP1/PIP interactions. As a
consequence really unique PP1 holoenzymes can exist, which
may allow for very specific counteracting and fine-tuning of
phosphorylation events conducted by the plethora of specific
kinases within the cell. It would be of major interest to solve
the structure of PP1/I-1 complexes as well, to better understand
the nature of the so far mainly phenomenologically described
interaction/inhibition.
Further reports showed that spinophilin is able to direct
PP1 to the membrane of the SR in cardiac myocytes.
Cardiomyocytes from spinophilin knock out mice revealed
significantly reduced length, increased Ca2+ amplitude as
well as maximal rate of Ca2+ rise during systole, decreased
shortening amplitude and maximal rate of shortening, while
b-adrenergic stimulation remained intact (Petzhold et al., 2011).
Mechanistic studies suggested that spinophilin-mediated PP1
targeting to RyR2 and Phospholamban lead to site-specific
enhanced dephosphorylation, thus evoking the phenotypic
consequences described in the latter study. Very recently the
group around Xander Wehrens transferred this knowledge into
better understanding of disease mechanisms in atrial fibrillation
putatively underlying deregulated PP1/spinophilin interactions
and subsequent hyperactivation of RyR2 (Chiang et al., 2014).
In detail they found that knockout of sphinophilin-1 resulted
in strongly reduced interaction of PP1 and RyR2, while RyR2
phosphorylation was significantly increased at serine (Ser) 2814
but unchanged at Ser2808. As a result RyR2s from spinophilin-1
KO mice showed the expected increase in RyR2 open probability
in lipid bilayer experiments, increased Ca2+ spark frequency in
isolated atrial myocytes, which could be reverted by CaMKII
inhibition, and most importantly increased atrial ectopy and
susceptibility to pacing-induced atrial fibrillation in vivo, which
could be reverted by crossing in phosphorylation-dead RyR2-
Ser2814A mice (Chiang et al., 2014). In summary this reports
showed the first time that decreased local PP1 regulation of
RyR2 contributes to RyR2 hyperactivity and promotion of atrial
fibrillation susceptibility. This milestone study may set the basis
for more exact examination of localized PP activity in CVDs, thus
enabling novel drug targeting strategies in the future.
The last chapter of PP-dependent PK activity regulation will
be opened in the upcoming section of this review. Hereby direct
activity control of PKs via PP-mediated dephosphorylation will
be discussed in light of a rapid molecular mechanism to achieve
direct feedback control of PK activity.
DIRECT CONTROL OF PROTEIN KINASE
EXPRESSION AND ACTIVITY BY PROTEIN
PHOSPHATASES
It is a basic principle that PKs themselves are activated by
(auto-)phosphorylation (Ubersax and Ferrell, 2007). In order to
avoid excessive PK activation it is necessary that in most cases
PK phosphorylation has to be reversible. Indeed several examples
(see also Table 1) show direct PP-mediated dephosphorylation of
PKs in cardiac cells. However, PP-mediated dephosphorylation of
two of the most abundant and essential PKs in cardiac myocytes,
namely PKA and CaMKII has only be studied in non-cardiac
tissues until today (Blitzer et al., 1998; Bradshaw et al., 2003;
Humphries et al., 2005; Otmakhov et al., 2015).
Dephosphorylation of PKA at position Thr-197 by PP2A was
shown in vitro and in vivo. Interestingly, dephosphorylation
activity strongly depends on oxidative state, which is
mechanistically mediated via the neighboring cysteine 199
(Humphries et al., 2005). CaMKII is auto-activated at position
Thr286 and can be dephosphorylated by PP1 and PP2B (Reese
et al., 2011). In this case the dephosphorylation activity in
dendritic spines is calcium dependent. It is tempting to speculate
that PKA as well as CaMKII are also direct substrates of PP-
mediated dephosphorylation in cardiac physiology and especially
in CVDs, thus predisposing further studies to clarify this
issue.
In addition, there is yet another possibility ofmore or less direct
control of PK activity by PP mediated initiation of alternative
splicing in cardiac myocytes. The best studied example in this
case is the CaMKIId-isoform, which plays an important role
during evolvement of heart failure and cardiac arrhythmias (Gray
and Heller Brown, 2014). Over- or deregulated expression of
single splicing variants of CaMKIId are sufficient to induce
cardiac hypertrophy, dilated cardiomyopathy and subsequent
heart failure in experimental animal models (Erickson, 2014).
Two studies have shown that reversible phosphorylation of the
splicing factor SF2/ASF by PKA and PP1 is able to change the
splicing pattern of CaMKIId and subsequently trigger functional
consequences on typical CaMKII substrates such as PLB (Gu et al.,
2011; Huang et al., 2014).
As described before Histones, Histone Deacetylases as well as
transcription and translation factors have also been identified as
PP substrates (Backs et al., 2006;Heijman et al., 2013; Kreusser and
Backs, 2014). All these components are necessary prerequisites
for (epi-)genetic control of PK activity. Finally, as CaMKIId is
by far not the only cardiac PK undergoing alternative splicing
it will be worth to examine this novel way of PP-mediated PK
regulation in more detail in the future. Regulation of alternative
splicing in cardiac myocytes has emerged as a highly innovative
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and novel drug target in multiple studies and would be interesting
to better understand the contribution of PPs in this regard.
This conclusion closes the gap toward the final chapter of this
review, which discusses the current state-of-the-art knowledge
regarding pharmacological PP activity control that may serve
as an additional or synergistic therapeutic approach toward
pharmacological compounds targeting PKs.
THERAPEUTIC PERSPECTIVE
The widespread tasks of PP1, PP2A, and PP2B in healthy and
diseased described in the chapter above, predispose the PPs as
novel drug targets. In order to receive similar attention as kinase
inhibitors, there are however still some challenges that have to be
tackled.
The most straightforward approach to block the activity
of an enzyme is the design of small molecules (SMOLs)
which bind to the active site of the enzyme, thus blocking
access for their endogenous substrates. Due to the very high
structural conservation in PP1’s catalytic site with that of
PP2A, it has remained difficult to specifically target the active
site of either phosphatase (Terrak et al., 2004; Cho and Xu,
2007). Nevertheless, some natural toxins such as calyculin,
cantharidin, tautomycin and okadaic acid did reveal subtle
selectivity between PP1 and PP2A in vitro and have thus been
employed the last decades to study the role of PP1 and PP2A
in cellular signaling processes (Hescheler et al., 1988; Aggen
et al., 1999; Fagerholm et al., 2010). Even better selectivity
is achieved by the endogenous inhibitors of PP1 and PP2A.
As an example the heat stable endogenous protein inhibitors
Inhibitor-1 as well as Inhibitor-2 specifically inhibit PP1 at very
low nanomolar concentrations without affecting the any other
known serine/threonine phosphatase (Kwon et al., 1997). The
usefulness of the latter inhibitors in functional assays or as
drug leads is limited by the size, availability, stability as well
as the cellular permeability of these proteins, but they could
nevertheless be used as starting points for peptide-based drug
design (Chatterjee and Kohn, 2013). Due to the multitude of
phosphatase substrates direct and solely targeting of a single
phosphatase catalytic subunit will putatively be insufficient or
induce serious toxic side effects so further strategies rely on
either disrupting the interaction between (a) the catalytic and
respective regulatory subunit or (b) the regulatory subunit and the
respective substrate. As a proof-of-concept specific modulators
of PP1 (and PP2A) holoenzymes have been developed not only
for the treatment of CVDs but also for the treatment of diabetes,
Parkinson’s disease and drug addiction (Uehata et al., 1997;
Armstrong et al., 1998; McConnell and Wadzinski, 2009; Yger
and Girault, 2011). Concrete examples are disruption of the
PP1/GADD34 complex by salubrinal or guanabenz or I-1/I-2
overexpression in rodent/pig models of myocardial infarction
(Boyce et al., 2005; Tsaytler et al., 2011; Liu et al., 2012;
Neuber et al., 2014). Moreover synthetic peptides containing
the PP1c-binding motif (RVxF) have been successfully used
to disrupt PP1 complexes in a neuronal and cardiac context,
inducing beneficial effects on synaptic transmission and PLB
phosphorylation (Reither et al., 2013; Sotoud et al., 2015). Thus,
clinical targeting of PPs side-by-side with PK inhibition may
represent a promising opportunity to treat CVDs in the near
future.
Last but not least we propose two novel strategies to further
enhance the feasibility of PP targeting drugs in CVDs: 1. Engaging
subcellular and isotype-specific control of PPs: a recent review
has highlighted the isotype-specific interaction of PP1 with
different regulatory subunits and inhibitors. Combined with
compartment-specific PP1 targeting this knowledge might lead
to the development of really specific PP targeting drugs. 2.
Combination of PK inhibitor and Phosphatase activating drugs
and vice versa: in order to increase potency of currently used
drugs, exact knowledge about the contribution of kinases and
phosphatases during reversible protein phosphorylation of a
specific substrate may help to develop novel and successful
combination therapies—similar to the success story of LCZ-
696/Entresto (Gu et al., 2010; Solomon et al., 2012; Jessup et al.,
2014; Desai et al., 2015).
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